Shiga Toxin 2

Clinical Therapeutics
Antibiotic-Mediated Modulations of Outer Membrane Vesicles in Enterohemorrhagic Escherichia coli O104:H4 and O157:H7
Andreas Bauwens, Lisa Kunsmann, Helge Karch, Alexander Mellmann, Martina Bielaszewska
Pharmacology
Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody, against Shiga-Like Toxin 2 in Healthy Adults and in Pediatric Patients Infected with Shiga-Like Toxin-Producing Escherichia coli
Eduardo L. López, Maria M. Contrini, Eduardo Glatstein, Silvia González Ayala, Roberto Santoro, Daniel Allende, Gustavo Ezcurra, Eduardo Teplitz, Tamotsu Koyama, Yoichi Matsumoto, Hiroaki Sato, Kazuaki Sakai, Satoru Hoshide, Keiji Komoriya, Takuya Morita, Ronald Harning, Sheldon Brookman
Pharmacology
Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers
Martin Bitzan, Ruth Poole, Mariam Mehran, Eric Sicard, Catherine Brockus, Claire Thuning-Roberson, Marc Rivière
Pharmacology
Shiga-Like Toxin II Impairs Hepatobiliary Transport of Doxorubicin in Rats by Down-Regulation of Hepatic P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2
Kazuhiko Hidemura, Ying Lan Zhao, Katsuki Ito, Akimasa Nakao, Yasuaki Tatsumi, Hiroaki Kanazawa, Kenzo Takagi, Michio Ohta, Takaaki Hasegawa
Pharmacology
Shiga-Like Toxin II Derived from Escherichia coli O157:H7 Modifies Renal Handling of Levofloxacin in Rats
Ying Lan Zhao, Xiao Bo Cen, Masafumi Ito, Keiko Yokoyama, Kenji Takagi, Kiyoyuki Kitaichi, Masayuki Nadai, Michio Ohta, Kenzo Takagi, Takaaki Hasegawa

Main menu

User menu

Search

Shiga Toxin 2